Phase III Randomized Study of Induction Chemotherapy Followed By Consolidation and Reinduction With or Without Late Intensification Followed By a Maintenance Regimen or Allogeneic Bone Marrow Transplantation in Infants With Acute Lymphoblastic Leukemia
Last Modified: 11/18/2009 First Published: 5/1/2001
Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Published Results
Trial Contact Information
Registry Information
Alternate Title
Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase III | Treatment | Closed | 365 days and under | ICU-INTERFANT99
UKCCSG-LK-1999-05, EU-20063, EU-20588, NCT00015873 |
Objectives - Determine the outcome of induction chemotherapy followed by consolidation and reinduction chemotherapy with or without late intensification chemotherapy followed by a maintenance regimen or allogeneic bone marrow transplantation in infants with newly diagnosed acute lymphoblastic leukemia.
- Determine the value of a late intensification course between reinduction and maintenance therapy in these patients.
- Determine the prognostic value of age, immunophenotype, WBC, day 15 bone marrow status, and MLL gene rearrangement in patients treated with these regimens.
Entry Criteria Disease Characteristics:
- Diagnosis of acute lymphoblastic leukemia (ALL)
- Newly diagnosed
- Morphological verification by cytochemistry and
immunophenotyping
- CNS or testicular leukemia at diagnosis allowed
- Trisomy 21 allowed
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - No prior chemotherapy for leukemia
Endocrine therapy: - At least 4 weeks since prior systemic
corticosteroids
- Prior inhaled steroids allowed
Radiotherapy: - No prior radiotherapy for leukemia
Surgery: Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: Hepatic: Renal: Expected Enrollment 350A total of 350 patients will be accrued for this study within 5 years. Outcomes Primary Outcome(s)Event-free survival at 3-4 years after diagnosis
Outline This is a partially randomized, multicenter study. Patients are
stratified according to risk (high vs standard). Patients receive induction therapy comprising prednisone orally or IV
three times a day on days 1-7; dexamethasone orally or IV three times a day on
days 8-35; vincristine IV on days 8, 16, 22, and 30; cytarabine IV over 30
minutes on days 8-21; daunorubicin IV over 60 minutes on days 8 and 9;
asparaginase IV over 1 hour or intramuscularly (IM) on days 15, 18, 22, 25,
29, and 33; methotrexate intrathecally (IT) on days 1 and 29; and cytarabine
IT on day 15. Patients receive prednisolone IT in combination with any dose
of intrathecal chemotherapy. Patients with CNS involvement receive additional
doses of methotrexate IT on days 8 and 22 and then weekly after day 29 until
there is no evidence of CNS leukemia. After achieving complete remission, patients receive MARAM chemotherapy
comprising oral mercaptopurine daily on days 1-14; methotrexate IV over 24
hours on days 1 and 8; leucovorin calcium orally or IV 36, 42, and 48 hours
after beginning each dose of oral methotrexate; methotrexate IT on days 2 and
9; cytarabine IV over 3 hours twice daily on days 15, 16, 22, and 23; and
asparaginase IV over 1 hour or IM on days 16 and 23. Patients receive
prednisolone IT in combination with any dose of intrathecal
methotrexate. At least 2 weeks after the completion of MARAM chemotherapy, patients
receive OCTADD chemotherapy comprising oral dexamethasone three times a day on
days 1-21; oral thioguanine daily on days 1-28 and 36-49; vincristine IV on
days 2, 8, 16, and 22; daunorubicin IV over 60 minutes on days 1, 8, 15, and
22; cytarabine IV on days 2-5, 9-12, 16-19, 23-26, 37-40, and 45-48;
cytarabine IT on days 1 and 15; and cyclophosphamide IV over 1 hour on days 36
and 49. Patients receive prednisolone IT in combination with any dose of
intrathecal methotrexate. Patients are randomized to one of two treatment arms for late
intensification therapy. - Arm I: Beginning at least 1 week after the completion of OCTADD
chemotherapy, patients receive VIMARAM chemotherapy comprising vincristine IV
on days 1, 8, 15, and 22; oral mercaptopurine daily on days 1-14; methotrexate
IV over 24 hours on days 1 and 8; leucovorin calcium orally or IV 36, 42, and
48 hours after the beginning of each dose of oral methotrexate; methotrexate
IT on days 2 and 9; cytarabine IV over 3 hours twice daily on days 15, 16, 22,
and 23; and asparaginase IV over 1 hour or IM on days 16 and 23. Patients
receive prednisolone IT in combination with any dose of intrathecal
methotrexate. Patients then receive the appropriate maintenance
therapy.
- Arm II: Patients do not receive VIMARAM chemotherapy but receive
appropriate maintenance therapy.
At least 2 weeks after the completion of the last course of
chemotherapy, patients receive maintenance therapy. Patients with a good
response to initial therapy with prednisone receive maintenance therapy
comprising oral dexamethasone three times daily on weeks 1 and 2; vincristine
IV on day 2 of weeks 1 and 2; oral mercaptopurine daily on weeks 1-14; and
oral methotrexate once weekly on weeks 1-14. Patients with a poor response to initial therapy with prednisone receive
maintenance therapy comprising oral mercaptopurine daily for weeks 1-14; oral
methotrexate once weekly for weeks 1-14; oral dexamethasone three times daily
for weeks 1 and 2; vincristine IV on day 2 of weeks 1 and 2; etoposide IV over
2 hours once weekly on weeks 8 and 9; and cytarabine IV over 1 hour once
weekly on weeks 8 and 9. Treatment repeats in both maintenance therapy regimens every 14 weeks
for a total of 3 courses. Patients also receive methotrexate IT on day 1 of
the first and third course of therapy and cytarabine IT on day 1 of the second
course of therapy. Patients receive prednisolone IT in combination with any
dose of intrathecal chemotherapy. Beginning after the completion of maintenance therapy, all patients
receive continuing maintenance therapy comprising oral mercaptopurine daily
and oral methotrexate once a week. Treatment continues until 104 weeks after
initial diagnosis. Patients with a poor response to initial therapy with prednisone may
receive allogeneic bone marrow transplantation if a donor is available. The
patient undergoes transplantation immediately after OCTADD chemotherapy rather
than being randomized and receiving maintenance therapy. These patients
receive conditioning regimen comprising oral busulfan four times a day on days
-8 to -5, etoposide IV over 4 hours on day -4, methotrexate IT on day -3, and
cyclophosphamide IV over 1 hour on days -3 and -2. Allogenic bone marrow is
transplanted on day 0. Patients then receive cyclosporine orally or IV on
days 1-180 as graft-versus-host disease prophylaxis. Patients are followed annually. Published ResultsLönnerholm G, Valsecchi MG, De Lorenzo P, et al.: Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 52 (5): 596-601, 2009.[PUBMED Abstract] van der Linden MH, Valsecchi MG, De Lorenzo P, et al.: Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood 114 (18): 3764-8, 2009.[PUBMED Abstract] Van der Velden VH, Corral L, Valsecchi MG, et al.: Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 23 (6): 1073-9, 2009.[PUBMED Abstract] Pieters R, Schrappe M, De Lorenzo P, et al.: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 (9583): 240-50, 2007.[PUBMED Abstract] Pieters R, Schrappe M, de Lorenzo P, et al.: Outcome of infants less than one year of age with acute lymphoblastic leukemia treated with the Interfant-99 protocol. [Abstract] Blood 108 (11): A-145, 2006.
Trial Contact Information
Trial Lead Organizations Dutch Childhood Oncology Group  | | | | Rob Pieters, MD, MSC, PhD, Protocol chair | | | |
| Registry Information | | | Official Title | | International Collaborative Treatment Protocol for Infants Under One Year with Acute Lymphoblastic Leukemia | | | Trial Start Date | | 1999-05-01 | | | Registered in ClinicalTrials.gov | | NCT00015873 1 | | | Date Submitted to PDQ | | 2001-02-06 | | | Information Last Verified | | 2006-10-05 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.
Table of Links
| 1 | http://clinicaltrials.gov/ct/show/NCT00015873 |
|
